Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose CKD-516 is a newly developed vascular disrupting agent. This phase I dose-escalation study of CKD-516 was conducted to determine maximum-tolerated dose (MTD), safety, pharma- cokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. Materials and Methods Patients received CKD-516 intravenously on D1 and D8 every 3 weeks, in a standard 3+3 design. Safety was evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.02 and response was assessed by Response Evaluation Criteria in Solid Tumor ver. 1.1. Results Twenty-three patients were treated with CKD-516 at seven dosing levels: 1 mg/m2/day (n=3), 2 mg/m2/day (n=3), 3.3 mg/m2/day (n=3), 5 mg/m2/day (n=3), 7 mg/m2/day (n=3), 9 mg/m2/day (n=6), and 12 mg/m2/day (n=2). Mean age was 54 and 56.5% of patients were male. Two dose-limiting toxicities, which were both grade 3 hypertension, were observed in two patients at 12 mg/m2/day. The MTD was determined as 12 mg/m2/day. Most common adverse events were gastrointestinal adverse events (diarrhea, 34.8% [30.4% grade 1/2, 13.0% grade 3]; nausea, 21.7% [all grade 1/2]; vomiting, 21.7% [all grade 1/2]), myalgia (17.4%, all grade 1/2), and abdominal pain (21.7% [21.7% grade 1/2, 4.3% grade 3]). The pharmacokinetic study showed the dose-linearity of all dosing levels. Among 23 patients, six patients (26.1%) showed stable disease. Median progression-free survival was 39 days (95% confidence interval, 37 to 41 days). Conclusion This study demonstrates feasibility of CKD-516, novel vascular disrupting agent, in patients with advanced solid tumor. MTD of CKD-516 was defined as 12 mg/m2/day on D1 and D8 every 3 weeks.
Abstract
Purpose CKD-516 is a newly developed vascular disrupting agent. This phase I dose-escalation study of CKD-516 was conducted to determine maximum-tolerated dose (MTD), safety, pharma- cokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. Materials and Methods Patients received CKD-516 intravenously on D1 and D8 every 3 weeks, in a standard 3+3 design. Safety was evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.02 and response was assessed by Response Evaluation Criteria in Solid Tumor ver. 1.1. Results Twenty-three patients were treated with CKD-516 at seven dosing levels: 1 mg/m2/day (n=3), 2 mg/m2/day (n=3), 3.3 mg/m2/day (n=3), 5 mg/m2/day (n=3), 7 mg/m2/day (n=3), 9 mg/m2/day (n=6), and 12 mg/m2/day (n=2). Mean age was 54 and 56.5% of patients were male. Two dose-limiting toxicities, which were both grade 3 hypertension, were observed in two patients at 12 mg/m2/day. The MTD was determined as 12 mg/m2/day. Most common adverse events were gastrointestinal adverse events (diarrhea, 34.8% [30.4% grade 1/2, 13.0% grade 3]; nausea, 21.7% [all grade 1/2]; vomiting, 21.7% [all grade 1/2]), myalgia (17.4%, all grade 1/2), and abdominal pain (21.7% [21.7% grade 1/2, 4.3% grade 3]). The pharmacokinetic study showed the dose-linearity of all dosing levels. Among 23 patients, six patients (26.1%) showed stable disease. Median progression-free survival was 39 days (95% confidence interval, 37 to 41 days). Conclusion This study demonstrates feasibility of CKD-516, novel vascular disrupting agent, in patients with advanced solid tumor. MTD of CKD-516 was defined as 12 mg/m2/day on D1 and D8 every 3 weeks.
참고문헌 (19)
- Dumontet C, "Microtubule-binding agents : a dynamic field of cancer therapeutics", Nat Rev Drug Discov, 9, pp.790~803 (2010)
- Siemann DW, "The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumorvascular disrupting agents", Cancer Treat Rev, 37, pp.63~74 (2011)
- Sessa C, "Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin(AVE8062)in patients with advanced solid tumors", Clin Cancer Res, 19, pp.4832~4842 (2013)
- Eskens FA, "A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin(AVE8062)and docetaxel in advanced solid tumours", Br J Cancer, 110, pp.2170~2177 (2014)
- Li J, "Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography", Br J Cancer, 110, pp.1727~1732 (2014)
- Lee J, "Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors", J Med Chem, 53, pp.6337~6354 (2010)
- Lee J, "Discovery of a potent tubulin polymerization inhibitor: synthesis and evaluation of water-soluble prodrugs of benzophenone analog", Bioorg Med Chem Lett, 20, pp.6327~6330 (2010)
- Moon CH, "CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model", Invest New Drugs, 32, pp.400~411 (2014)
- Kim YI, "Enhanced efficacy of CKD-516 in combination with doxorubicin : pre-clinical evaluation using a hepatocellular carcinoma xenograft model", Anticancer Res, 34, pp.1715~1722 (2014)
- Rustin GJ, "Phase I clinical trial of weekly combretastatin A4phosphate : clinical and pharmacokinetic results", J Clin Oncol, 21, pp.2815~2822 (2003)
- Stevenson JP, "Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer : magnetic resonance imaging evidence for altered tumor blood flow", J Clin Oncol, 21, pp.4428~4438 (2003)
- Dowlati A, "A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer", Cancer Res, 62, pp.3408~3416 (2002)
- Beerepoot LV, "Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors", J Clin Oncol, 24, pp.1491~1498 (2006)
- Mita MM, "Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358)in patients with solid tumors or lymphomas", Clin Cancer Res, 16, pp.5892~5899 (2010)
- Hande KR, "The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent : results of a phase 1 study", Clin Cancer Res, 12, pp.2834~2840 (2006)
- Joo I, "Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors", Radiology, 272, pp.417~426 (2014)
- 주이진, "Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors", ULTRASONOGRAPHY, 33(1), pp.18~25 (2014), 대한초음파의학회[DOI]
- Kim KW, "Free-breathing dynamic contrast-enhanced MRI of the abdomen and chest using a radial gradient echo sequence with K-space weighted image contrast(KWIC)", Eur Radiol, 23, pp.1352~1360 (2013)
- Baguley BC, "Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer", Clin Lung Cancer, 12, pp.81~86 (2011)